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ABSTRACT  
Background: Atrial fibrillation (AF) is associated with high morbidity and mortality, 
also amongst anticoagulated patients. Our aim was to evaluate the predictive role for 
long-term mortality of a series of risk stratification scores associated with 
cardiovascular or thromboembolic outcomes (CHADS2, CHA2DS2-VASc, ATRIA, 
TIMI-AF), and bleeding complications (HAS-BLED) in an unselected population of 
patients with AF. 
Methods: Single center, observational, prospective registry of consecutive patients 
with AF, undergoing clinical/echocardiographic evaluation in a University Hospital, 
as either in-patients or out-patients. We assessed the role of each single score as 
predictors of long-term survival according to clinical setting. 
Results: We enrolled 1051 patients, mean age 72±12 years, who were followed for 
797±298 days.  All the tested scores showed a good performance in prediction of 
mortality, together with several clinical factors (older age, chronic heart failure, 
diabetes, renal impairment, previous transient ischemic attack, left ventricular ejection 
fraction). The values at C-statistics ranged between modest (0.608-0.684) of 
inpatients to good (0.708-0.751) in outpatients without any statistical difference 
between the scores, excepted a lower performance of HAD-BLED. 
Conclusions: Risk scores currently adopted for decision making on starting oral 
anticoagulation provide good prediction of long-term survival in unselected AF 
patients, especially in the outpatient setting.   
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Introduction 
Atrial fibrillation (AF) is associated with high morbidity and mortality, which is still 
evident amongst anticoagulated patients
1–5
.  To improve effective clinical decision-
making several clinical scoring systems (see Supplementary Table 1) have been 
developed to stratify the risk of thromboembolic events
6–8
 , bleeding complications 
9
 
risk of adverse cardiovascular events
10
 and the identification of patients for whom a 
therapeutic benefit of novel oral anticoagulants (NOACs) over Vitamin K antagonist 
(VKA) 
11
. Previous studies have shown that the CHADS2 and CHA2 DS2 –VASc 
scores may have some predictive role for survival of AF and non-AF patients both in 
inpatient and outpatient settings
12–17
 but the adoption in non-AF patients has been 
criticized
18
. 
Our aim was to evaluate the predictive role for long-term mortality of a series of 
clinical risk stratification scores associated with cardiovascular or thromboembolic 
outcomes (ATRIA, CHADS2, CHA2DS2-VASc, TIMI-AF), and bleeding 
complications (HAS-BLED) in an unselected population of patients with AF, also 
considering the site of enrolment (inpatient vs. outpatient setting). 
 
 
Materials and Methods 
We performed a single centre observational, prospective registry including 
consecutive patients with a diagnosis of AF referred to a tertiary teaching Hospital. 
The study design has been previously reported 
19. In brief, we enrolled patients with ≥ 
1 ECG-proved episode of AF within 1 year before screening. Patients were included 
if ≥ 18 years old and basic echocardiographic data were available (i.e. left ventricular 
ejection fraction, left atrial diameter and quantification of valvular dysfunctions). The 
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local ethical committee approved the study and written informed consent was 
obtained by all the participants. The investigation was conducted in accordance with 
the principles expressed in the Declaration of Helsinki. 
Data collection was performed at patient inclusion (baseline) and at 1-year follow-up. 
Baseline evaluation considered: (a) patient demographics, (b) medical history, (c) AF 
characteristics, (d) AF-related symptoms, (e) AF management strategy, (f) standard 
laboratory assay and (g) complete pharmacological therapy. For each patient we 
calculated ATRIA, CHADS2, CHA2DS2-VASc, HAS-BLED, and TIMI-AF scores 
(Supplementary table 1). The same evaluation was performed every 12 months for up 
to three years of follow-up. At each review check we also evaluated overall patient 
status and the events occurred since baseline, in particular: (a) hospital admissions, 
(b) cardiovascular interventions, (c) instrumental evaluations. Between the two fixed 
face to face checks we performed telephonic surveillance (between months 3 to 9 
after each check) to improve compliance to the protocol. The same was performed to 
exclude death or major clinical events for patients not performing the periodical face 
to face check. To classify the mode of death we performed parents interview and 
revision of death certificate and all the available clinical records by two different 
operators.  
 
Statistical analysis: 
Continuous variables with normal distribution are expressed as means ± standard 
deviation (median and interquartile range (IQR) for continuous variables without 
normal distribution). Categorical variables are expressed as number of patients and 
frequencies/percentage. Comparisons between enrolment and follow-up data were 
performed using the paired Student's t-test for continuous normally distributed 
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variables, χ2-test for categorical variables and non parametric equivalent tests for 
other type of variables. Cox proportional hazards analysis was used to identify scores 
as independent predictors of overall mortality and the results are presented as hazard 
ratio (HR), confidence interval and p-value. Models building follows a backward-
stepwise approach, the test of term significance is the Wald chi-square test with cutoff 
p value of 0.1 for removal and 0.05 for addition.  The Harrell’s C-statistic and the 
confidence intervals were used to assess the goodness of fit, or discriminatory value, 
of Cox regression models and to compare their predictive power. Kaplan-Meier 
curves for overall survival according to the various scoring systems were constructed. 
Data analysis was performed with the statistical software Stata/SE 14.2 for Windows ( 
StataCorp LLC, College Station TX, USA) and SPSS 23.0 ( SPSS Statistics/IBM 
Corp, Chicago IL, USA).  
 
Results 
We enrolled 1051 patients aged 72±12 years. The main enrolment site was cardiology 
ward and day-hospital (71.1%) followed by outpatients clinic (28.9%). Baseline 
clinical and echocardiographic characteristics of the enrolled population are reported 
in table 1 according to outpatient/inpatient status at the time of enrolment.  In general 
the most common subtype was permanent AF (44.8%) justifying a rate-control 
strategy in a significant proportion of the enrolled patients (65.0%). Moreover, 48.3% 
of the overall patients never experienced any typical AF-related symptom, with 
palpitations and dyspnoea being the most represented among the remaining subjects. 
Notably, inpatients were sicker with respect to outpatients, with a higher proportion of 
permanent AF and only in a minority of the patients AF was the principal 
cardiovascular problem leading to access to medical intervention.   
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The mean baseline values for the various clinical scores were as follows: ATRIA 
5.6±2.9, CHADS2 2.0±1.3, CHA2DS2-VASc 3.7±1.9, HAS-BLED 2.0±0.9, and 
TIMI-AF 5.7±2.1.   
After a mean follow-up of 797±298 days (median 730 days; range 368-1102 days) 
166/1051 (15.8%) patients died. The causes of death were as follows: non-
cardiovascular (38.0%. Among them the leading causes were cancer, 12.7% of the 
total, infections 10.4% and trauma 3.6%), heart failure (30.7%), stroke (4.2%) other 
cardiovascular aetiologies (14.5%). In 21 patients (12.7%) the aetiology remained 
undetermined. Notably inpatients presented a higher overall death at follow-up 
without a significantly different cause of the event, despite a trend for non-
cardiovascular causes in outpatients (Figure 1). 
Univariate and multivariate regression 
We first performed a univariate Cox regression analysis including all the tested scores 
together with the single characteristics included in these scores (supplementary table 
2).  Using the significant characteristics from the univariate analysis, we performed 
multivariate regression analysis among the single factors which showed six factors 
that were independently associated with overall survival (Model 1).  Notably the 
mode of access to medical evaluation (inpatient vs. outpatient) presented a p value for 
interaction <0.05 for each score with exception of TIMI-AF, for which however was 
present a trend (p=0.061). Conversely, the presence/absence of anticoagulation 
(performed as a sensitivity analysis) was not associated with a significant p value for 
interaction for each scoring system included in the analysis. According to these 
findings we provided two additional model in the multivariate regression analysis for 
inpatient (Model 2) and outpatients (Model 3). Notably only left ventricular ejection 
fraction and diabetes were present in all the models. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Figure 2 shows Kaplan Meier curves for 1-year survival for each of the different 
scores divided into low to high risks categories, as defined in the literature
20–22
.   
Predictive value 
We compared the five risk scores in predicting overall survival with C-Harrell test, 
together with the probability provided by the multivariate Cox regression analysis 
(used as a positive comparator).  As show in table 2 the performance of the all scores 
for the prediction of death was good with exception of HAS-BLED score. Of note, the 
probability assessed by the model provided by the multivariate Cox regression 
analysis performed better than each score in general population, but this finding 
seems to be driven by the inpatient subgroup, while in outpatients the C statistic the 
model and “standard” score did not produce any significant difference.  
Discussion 
In our study we compared the five clinical risk scores used in current clinical practice 
for the management of patients with AF in their capability of predicting mortality in a 
relatively unselected prospectively enrolled group of AF patients. All scores showed a 
good performance in prediction of mortality using univariate Cox regression analysis, 
as did several individual factors included in their calculation: age, renal impairment, 
diabetes, heart failure, left ventricular ejection fraction and previous transient 
ischemic attack. Since the development of CHADS2 several scoring systems have 
been developed for AF patients to improve risk stratification for several events: 
stroke, bleeding complications, cardiovascular events. However, we have no guide on 
how to integrate them in clinical practice. This is a relevant topic considering that the 
experts who were in charge of the last AF guidelines felt the need to modify the 
practical use of HAS-BLED (and other scoring system for stratifying the bleeding 
risk) since for many clinicians a high score was seen as a barrier to anticoagulation
23
. 
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Few studies compared CHADS2 and CHA2DS2-VASc scores for prediction of overall 
survival in more selected populations with or without AF
12–14
. The HAS-BLED score 
was also tested in one of these studies in a group of patients undergoing PCI 
24
 with a 
relatively lower performance with respect to CHADS2 and CHA2DS2-VASc in 
accordance to our results.  
Our results show that, beyond the stratification of the risk of stroke, two scores like 
CHADS2 and CHA2DS2-VASc, which are based on a limited set of data, are effective 
in predicting overall mortality without the need for additional information such as 
laboratory tests (e.g. creatinine, proteinuria or haemoglobin) or echocardiography, 
which are less ready available especially in outpatient settings. In this view, the 
second most important result of our study is that prediction of long-term mortality 
was significantly affected by the setting (see Figure 1,2) as documented by the 
different factors included in the final multivariate models for inpatients and 
outpatients. This can be driven by the differences in the two subgroups in terms of AF 
type and comorbidities. But it can also be the effect of other factors (e.g. variability of 
renal function leading to greater imprecision in outpatients, or acute/subacute events 
leading to hospitalization).  Notably, despite the deep differences in these two 
subgroups of patients all scores, with the exception of HAS-BLED, performed very 
well for prediction of mortality without a significant superiority of any of them. 
However, only in the outpatient settings the results were equivalent to the multivariate 
model. This is a very important result since it shows a simple scoring systems, like 
CHADS2 and CHA2DS2-VASc, is as good as an ad-hoc score to predict mortality in 
an unselected population of AF outpatients. A further consideration has to be made on 
the possible differences in AF treatment between inpatient and outpatients that could 
also explain the different outcomes, in particular regarding thromboembolic 
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prophylaxis
25
. Notably, in our cohort we found no difference between inpatient and 
outpatients in terms of anticoagulant prescription without interaction with the 
predictive role of each score, while our high prescription rate (respectively 90% vs. 
86%; p=NS) reflects current trends in AF management, as reported by the EORP-AF 
registry
26
, increasing transferability of our results.  Conversely, the study by 
Mikkelsen et al. was related to a previous period (2002-2011) with a lower use of 
anticoagulation (about 60% for outpatient and 40% for inpatients). It could be obvious 
but it is relevant to consider that the results of all these scores vary with time leading 
to the question on how frequently should be reassessed each score in the specific 
patient. According to our results a re-evaluation every 12-24 months or soon after 
hospital admission should provide the best compromise. Moreover, in less stable 
patients more “complete” scores, like TIMI-AF, should be considered. However, 
further evaluation are needed to confirm a similar approach. Finally, several other risk 
factors are not included by the scores we considered (e.g. AF burden, atrial dilatation, 
additional comorbidities, neurohormones) that could potentially help in predicting 
long-term survival. Despite these considerations the practical implications of our 
findings are significant: in clinical practice this could improve personalization of 
patient follow-up by targeting a closer clinical monitoring to patients at increased risk 
of thromboembolic events. Moreover, the value of these scores can help comparing 
the risk of long-term mortality of different populations and/or subgroups
27
. 
Limitations 
The most important limitation of our study is its observational nature and related to a 
single University Hospital. The sample size is relatively limited, with a relatively high 
mean value of CHA2DS2-VASc score therefore may be not fully generalizable to all 
AF patients, especially to less sick patients. 
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Conclusions 
Clinical risk scores associated with cardiovascular or thromboembolic outcomes 
improve prediction of long-term survival in unselected AF patients. In particular, we 
found no difference in predicting value of simple scores (like CHADS2 and 
CHA2DS2-VASc) with respects to scores requiring integration of laboratory and 
echocardiography data. Their performance seems to be higher in outpatient (vs. 
inpatient) settings were personalization of patient monitoring can improve everyday 
clinical practice.  
   
Funding: This research did not receive any specific grant from funding agencies in 
the public, commercial, or not-for-profit sectors. 
 
FIGURE LEGENDS 
 
Figure 1. Overall survival and cause of death according to clinical settings. 
Legend: CV=cardiovascular; HF=heart failure; pts=patients. 
 
Figure 2. Kaplan Meier curves for 1-year survival for each of the different scores 
divided into low to high risks categories according to clinical settings. 
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HIGHLIGTS 
 
 We found that five scoring systems showed a good performance in prediction 
of long-term mortality in a relatively unselected cohort of patients; 
 No significant difference in prediction performance was seen among the five 
scores, with the exception of HASBLED; 
 In particular, we found no difference in predicting value of simple scores (like 
CHADS2 and CHA2DS2-VASc) with respects to scores requiring integration 
of laboratory and echocardiography data. 
 Prediction of long-term mortality is affected by the setting, with a better 
performance for all the scores in the outpatient settings; 
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